Interview on Raw Materials for Cell & Gene Therapy

April 2017

Exploring regulatory and supply issues



Bernd Leistler, our Vice President Development & Production, was interviewed by the Cell & Gene Therapy Insights about our vision on the regulatory and supply issues for raw materials.

The cell and gene therapy sector has seen a rapid expansion and maturation as more companies are approaching late-stage clinical development and market authorization. We see this reflected in an increased demand for GMP-grade raw materials and discussions about their quality requirements and regulatory guidance. Please click here to download the interview and read about our vision on the regulatory and supply issues for raw materials.

The interview was published in the Cell & Gene Therapy Insights spotlight “Raw materials for cell & gene therapy: getting it right from the start”. You can access the complete spotlight here.

Cell and Gene Therapy Insights is an online, open access, peer-reviewed journal with a translational focus. Key scientific, regulatory, business and manufacturing challenges and advances are addressed through publication of original research, editorials and interviews. These are complimented by daily news, webinars, and commercial and clinical trial updates. All content is available free of charge, and you can register at http://insights.bio/cell-and-gene-therapy-insights/.